D
Alnylam Pharmaceuticals, Inc. ALNY
$246.66 -$2.57-1.03%
Recommendation
Sell
Prev Close
$249.23
Volume
234,245
Avg Vol (90D)
746,856
Market Cap
$32.26B
Dividend & Yield
--
52-Week Range
$141.98 - $304.39
P/E (TTM)
--
EPS (TTM)
-$2.17
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Good
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Fair
Volatility Index
Fair
Dividend Index
--
Headlines
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced
3/6/2025 - Simply Wall St
Alnylam Pharmaceuticals Announces Retirement of Co-Founder Dr. Phillip A. Sharp
3/5/2025 - GuruFocus
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
3/5/2025 - Business Wire
Plato Investment Management Ltd Purchases 845 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
3/4/2025 - Ticker Report
Grandfield & Dodd LLC Acquires 1,149 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
3/3/2025 - MarketBeat
LGT Fund Management Co Ltd. Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
3/3/2025 - Ticker Report
LGT Fund Management Co Ltd. Makes New $2.37 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
3/3/2025 - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Truist Financial Corp
3/2/2025 - MarketBeat
Proficio Capital Partners LLC Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
3/1/2025 - Ticker Report
Proficio Capital Partners LLC Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
3/1/2025 - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Outperform" Rating at William Blair
3/1/2025 - Ticker Report
Alnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reiterated at William Blair
2/27/2025 - MarketBeat
Allegiance Financial Group Advisory Services LLC Invests $228,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
2/27/2025 - Ticker Report
Y Intercept Hong Kong Ltd Purchases New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
2/27/2025 - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
2/27/2025 - Ticker Report
Alnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reiterated at Royal Bank of Canada
2/26/2025 - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Chardan Capital
2/26/2025 - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Buy Rating from Needham & Company LLC
2/26/2025 - Ticker Report
Needham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2/26/2025 - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Reduced by GraniteShares Advisors LLC
2/26/2025 - Ticker Report
Notable Two Hundred Day Moving Average Cross - ALNY
2/25/2025 - Market News Video
Alnylam Pharmaceuticals Inc (ALNY) Showcases R&D Progress and Platform Innovation at R&D Day
2/25/2025 - GuruFocus
Illinois Municipal Retirement Fund Buys 25,298 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
2/25/2025 - Ticker Report
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Increased by Illinois Municipal Retirement Fund
2/25/2025 - MarketBeat
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
2/25/2025 - Business Wire
Income Statement
Total Revenue (TTM)
$2.25B
EBITDA (TTM)
-$120.22M
EBIT (TTM)
-$176.89M
Net Income (TTM)
-$278.16M
Balance Sheet
Total Assets (Q)
$4.24B
Total Debt (Q)
$2.74B
Total Liabilities (Q)
$4.17B
Book Value Per Share (Q)
$0.5189
Cash Flow
Cash from Operations (TTM)
-$8.31M
Cash from Investing (TTM)
-$116.84M
Cash from Financing (TTM)
$294.16M
Net Change in Cash (TTM)
$153.77M
Filings
Filing Date
Thursday, February 13, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
1.24
7-Day Total Return
0.60%
30-Day Total Return
-7.46%
60-Day Total Return
-2.05%
90-Day Total Return
-16.35%
Year to Date Total Return
5.58%
1-Year Total Return
64.81%
2-Year Total Return
23.52%
3-Year Total Return
51.33%
5-Year Total Return
117.53%
52-week Low
Apr 25, 2024 - $141.98
52-week High
Oct 17, 2024 - $304.39
Valuation
Market Cap
$32.26B - Large Cap
Enterprise Value
$32.31B
Price/Sales (TTM)
14.31
Price/Book (Q)
480.30
Dividends and Shares
Shares Outstanding
129.12M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.alnylam.com
Phone Number
617 551 8200
Address
675 West Kendall Street
Cambridge, MA 02142
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated... more
NASDAQ 03/06/2025 1:33PM Eastern Quotes delayed
Weiss Ratings